Erasca wins FDA Fast Track for pan-RAS molecular glue in PDAC
Erasca has secured FDA Fast Track Designation (FTD) for ERAS-0015, its oral pan-RAS molecular glue, in patients with metastatic pancreatic adenocarcinoma. The San Diego-based precision oncology company said the designation follows encouraging early clinical activity in its ongoing AURORAS-1 Phase 1 trial, and is intended to facilitate closer FDA engagement as it plans a Phase 3 programme in pancreatic cancer alongside two potentially pivotal trials in lung cancer.
In July 2026, Erasca reported updated preliminary data from AURORAS-1 showing a 57% unconfirmed overall response rate at eight weeks in patients with second-line or later KRAS G12X pancreatic ductal adenocarcinoma (PDAC) treated with ERAS-0015 monotherapy at the recommended dose for expansion of 32 mg once daily. The company noted that all responding patients remained on treatment as of the May 2026 data cut-off, and described the tolerability profile as favourable. Additional monotherapy expansion data and results from combination dose escalation cohorts, including a panitumumab combination arm, are expected in the first half of 2027.
Jonathan Lim, chairman, chief executive and co-founder of Erasca, said the FTD "reflects the urgent need for new therapies for patients with metastatic pancreatic cancer" and that the designation, together with the clinical activity observed, positions the company to advance ERAS-0015 rapidly. He highlighted plans for direct FDA engagement on the Phase 3 design.
What makes ERAS-0015 distinct
ERAS-0015 is designed as a pan-RAS inhibitor, meaning it is intended to suppress signalling across multiple RAS variants rather than targeting a single mutation such as KRAS G12C, the basis of the approved agents sotorasib and adagrasib. The molecular glue mechanism is also mechanistically distinct from the covalent inhibitor approach used by first-generation KRAS inhibitors. Erasca has also highlighted the candidate's ability to inhibit wild-type RAS variants, which the company argues could help prevent acquired resistance to mutant-selective drugs.
Fast Track status does not alter the regulatory approval standard but allows for more frequent FDA interactions and may open eligibility for accelerated or rolling review if relevant criteria are met.
Competitive landscape and regulatory read-across
Pancreatic cancer is one of the most closely watched areas in oncology drug development. KRAS mutations, present in roughly 90% of PDAC cases, have historically been considered undruggable. The approval of KRAS G12C inhibitors in non-small cell lung cancer has energised RAS-directed drug discovery, and a number of companies are now pursuing broader pan-RAS or multi-mutant strategies. Revolution Medicines, which Erasca itself names in its risk disclosures as a potential patent litigation counterparty, is among the most advanced in pan-RAS inhibition. Mirati Therapeutics and others have also explored combination strategies in KRAS-driven tumours.
The 57% unconfirmed response rate in second-line PDAC, if validated in larger cohorts, would represent a meaningful result in an indication where second-line options remain limited and median overall survival is measured in months. Pancreatic cancer has benefited from a series of regulatory pathway designations in recent years, including Breakthrough Therapy Designation for several agents, reflecting the FDA's stated commitment to accelerating development in the space. For Erasca, the near-term value-inflection point will be the H1 2027 combination data readout, particularly the panitumumab arm, since EGFR co-inhibition has shown promise in pre-clinical models of KRAS-mutant disease. Investors will also be watching for clarity on trial design and endpoints as the company moves toward a Phase 3 submission strategy.